Search the Newsreel

Why Mccoy Global Inc stock is rising today

Tapestry's Coach International Growth Could Offset North America Slowdown, Morgan Stanley Says

Tapestry's (TPR) fiscal Q4 results showed a slowdown in Coach's North American business, but stronger international growth could support the company's growth trajectory, Morgan Stanley said.Coach North America growth slowed to 10% year over year in Q4, while international sales Silver Upgrade to read …

Tapestry (TPR) Is Down 20.7% After Soft 2027 Outlook Tempers Dividend Hike And Buybacks

Tapestry, Inc. has already reported fourth-quarter and full-year 2026 results, with sales rising to US$1,876.6 million and US$8,004.2 million respectively, alongside a swing from loss to profit and a Board-approved 16% increase in the quarterly dividend to US$0.4625 per share. The company also completed …

TPR Q4 Earnings Call Puts Coach Growth Durability in Focus

Tapestry, Inc. TPR used its fiscal fourth-quarter call to emphasize that Coach can sustain growth in fiscal 2027 despite a more measured second-half cadence. TPR reported adjusted earnings of $1.32 per share, which beat the Zacks Consensus Estimate of $1.26. Revenues of $1,876.6 million …

Tapestry (TPR) To Report Earnings Tomorrow: Here Is What To Expect

Tapestry (TPR) To Report Earnings Tomorrow: Here Is What To Expect Luxury fashion conglomerate Tapestry (NYSE:TPR) will be announcing earnings results this Thursday morning. Here's what to look for. Tapestry beat analysts' revenue expectations last quarter, reporting revenues of $1.92 billion, up 21.2% year …

Tapestry Inc (TPR) (Q4 2026) Earnings Call Highlights: Record Results and Strategic Momentum ...

This article first appeared on GuruFocus. Revenue: Fiscal 2026 revenue reached $8 billion, growing 17% on a pro forma constant currency basis. Operating Margin: Expanded by 340 basis points to over 23%. Earnings Per Share (EPS): Increased 38% to $7.05. Customer Acquisition: Welcomed 11 …

Tapestry Triggers Sell Signal Despite Strong Earnings. Here's Why.

Tapestry gave lackluster guidance early Thursday as Kate Spade challenges persist, offsetting an earnings and revenue beat for the fiscal fourth quarter. Intraday, TPR stock plunged below key levels, setting off a sell signal. Continue Reading

Tapestry Tumbles 17% as Kate Spade Weakness Hits Outlook

This article first appeared on GuruFocus. Tapestry Inc. (TPR, Financials) shares slid as high as 16.9% after the owner of Coach and Kate Spade gave a more cautious annual sales projection. Warning! GuruFocus has detected 5 Warning Sign with TPR. Is TPR fairly valued? …

Tapestry Stock Plunges 15% as Kate Spade Clouds Outlook

This article first appeared on GuruFocus. Tapestry (NYSE:TPR), the luxury-fashion powerhouse behind Coach and Kate Spade, plunged roughly 15.2% in Thursday's opening trading. The quarter was not the problem. Sales jumped 8.9% to $1.88 billion, while adjusted earnings of $1.32 per share beat the …

Tapestry, Inc. Q4 2026 Earnings Call Summary

Tapestry, Inc. Q4 2026 Earnings Call Summary - Moby Strategic Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Achieved three-year …

Tapestry raises dividend by 15.6% to $0.4625

* Tapestry (TPR [https://seekingalpha.com/symbol/TPR]) declares $0.4625/share quarterly dividend [https://seekingalpha.com/pr/20617829-tapestry-inc-reports-fiscal-2026-fourth-quarter-and-full-year-results], 15.6% increase from prior dividend of $0.4000. * Forward yield [https://seekingalpha.com/symbol/TPR/dividends/yield?source=news_bullet] 1.41% * Payable Sept. 21; for shareholders of record Sept. 4; ex-div Sept. 4. * See TPR Dividend Scorecard, Yield Chart, & Dividend Growth. …

Tapestry Is the Worst Stock in the S&P 500 Today. Blame Guidance.

The soft outlook overshadowed Tapestry’s fiscal fourth-quarter earnings and revenue, which beat analyst expectations. Continue Reading

Tapestry Q4 Earnings Beat on Coach Growth & Margin Expansion

Tapestry, Inc. TPR reported fourth-quarter fiscal 2026 results, with adjusted earnings beating the Zacks Consensus Estimate while revenues met expectations. The company's bottom line benefited from robust Coach brand momentum, broad-based geographic growth, higher margins and disciplined cost management. Tapestry achieved its Investor Day …

Tapestry (NYSE:TPR) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops On Weak Guidance

Tapestry (NYSE:TPR) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops On Weak Guidance Luxury fashion conglomerate Tapestry (NYSE:TPR) met Wall Street's revenue expectations in Q2 CY2026, with sales up 8.9% year on year to $1.88 billion. The company's outlook for the …

(TPR) Tapestry, Inc. erwartet im 1. Quartal ein bereinigtes Ergebnis je Aktie von 1,55 USD

Tapestry, Inc. Reports Fiscal 2026 Fourth Quarter and Full Year Results

Achieved Tapestry Investor Day Revenue, Operating Margin, and EPS Targets Two Years Ahead of Plan Delivered Fourth Quarter Revenue of $1.9 Billion, an Increase of 9% Versus Prior Year or 11% on a Pro Forma Constant Currency Basis, led by a 15% (+14% Constant …

Decoy Therapeutics: Q2 Earnings Snapshot

How To Earn $500 A Month From Tapestry Stock Ahead Of Q4 Earnings

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. As fashion company Tapestry, Inc. prepares to release fourth-quarter earnings before the opening bell on Thursday, Aug. 13, investors may be eyeing potential gains from the company's …

Decoy Therapeutics (DCOY) posts wider Q2 loss, flags going-concern and Nasdaq risks

Decoy Therapeutics (DCOY) reported a wider net loss of $2.37 million in Q2 2026, compared to $957,825 a year earlier, and a six-month net loss of $4.59 million. The biotechnology company disclosed substantial doubt about its ability to continue as a going concern, projecting …

Chardan Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA)

Chardan Capital has reiterated its "Buy" rating for Coya Therapeutics (NASDAQ:COYA) and set a $14 price target, indicating a potential 192% upside. Analyst sentiment for the stock is generally positive, with a "Moderate Buy" consensus and an average price target of $15.33. The company …

Coya Therapeutics (NASDAQ:COYA) Posts Earnings Results, Beats Estimates By $0.08 EPS

Coya Therapeutics (NASDAQ:COYA) reported a quarterly loss of $0.28 per share, surpassing analyst expectations by $0.08. Despite beating estimates, the company showed negative net margins and return on equity, with shares rising 0.6% during Tuesday trading. Analysts maintain a "Moderate Buy" consensus, and institutional …

Form 8K Coya Therapeutics Inc For: 11 August By Investing.com

This article from Investing.com is a brief notice about Coya Therapeutics Inc.'s Form 8K filing for August 11. It simply states that the Form 8K has been published and provides no further details about the content of the filing. The article also includes stock …

Coya Therapeutics posts investor presentation on Treg-directed combination therapy for neurodegenerative diseases

Coya Therapeutics presented an investor update on its Treg-directed combination therapy for neurodegenerative diseases, highlighting COYA 302 as its lead program. An ALS Phase 2 readout is anticipated in Q1 2027, with enrollment for the ALSTARS Phase 2 trial expected to conclude in H2 …

Coya Therapeutics (NASDAQ: COYA) details Q2 2026 results, ALS Fast Track and cash runway

Coya Therapeutics announced its Q2 2026 financial results, highlighting progress on its lead program, COYA 302, for ALS and frontotemporal dementia. The company received FDA Fast Track Designation for COYA 302 in ALS and expects to complete Phase 2 enrollment for the ALSTARS ALS …

Coya Therapeutics Reports Q2 Net Loss of $6.6 Million

Coya Therapeutics reported a Q2 net loss of $6.6 million, an increase from $6.1 million in the prior year, with a net loss per share of $0.28. The company ended the quarter with $43.2 million in cash, sufficient to fund operations past its Phase …

Coya Therapeutics (COYA) Earnings Date and Reports 2026

McCoy Global Revenue Slumps on Mideast Turmoil but Liquidity Strengthens

Coya Therapeutics, Inc. Appoints Mark H. Pavao to Its Audit Committee of Board, Effective August 7, 2026

Coya Therapeutics, Inc. announced the appointment of Mark H. Pavao to its Audit Committee of the Board, effective August 6, 2026. This appointment was made upon the recommendation of the Nominating and Corporate Governance Committee. Following this change, the Audit Committee now includes Dr. …

Coya Therapeutics (NASDAQ: COYA) names Mark Pavao to its Audit Committee

Coya Therapeutics (NASDAQ: COYA) has announced the appointment of Mark H. Pavao to its Audit Committee, effective immediately. This follows his prior appointment to the Board of Directors on April 1, 2026, which was initially disclosed without committee assignments. The Audit Committee now includes …

McCoy Global Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

McCoy Global: 2Q Reflected Impact of Extended Geopolitical Instability in Middle East, Including Logistics Constraints, Delayed Customer Shipments and Deferred Cap Purchase Decisions >MCB.T

Earnings Flash (MCB.TO) McCoy Global Inc. Reports Q2 Revenue C$17.2M, vs. FactSet Est of C$11.0M

Earnings Flash (MCB.TO) McCoy Global Inc. Posts Nil Q2 EPS vs. FactSet Est of C$-0.03